-
Posted by
Two Blokes Jul 7 -
Filed in
Stock
-
5 views
Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage melanoma patients Halifax, Nova Scotia--(Newsfile Corp. - July 7, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that a first dosing has been achieved in the previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment. Dr. Carman Giacomantonio, Sona's CMO, commented, "Our unique therapy aims to modify tumors making them more visible to the immune system with a view to enabling an elimination of the cancer.
